Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial | Zendy

Anthony J. GarciaPrats | Zendy; Elin M. Svensson | Zendy; Jana Winckler | Zendy; Heather R. Draper | Zendy; Lee Fairlie | Zendy; Louvina E. van der Laan | Zendy; Masebole Masenya | Zendy; H. Simon Schaaf | Zendy; Lubbe Wiesner | Zendy; Jennifer Norman | Zendy; Rob E. Aarnoutse | Zendy; Mats O. Karlsson | Zendy; Paolo Denti | Zendy; Anneke C. Hesseling | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Author(s) -

Anthony J. GarciaPrats,

Elin M. Svensson,

Jana Winckler,

Heather R. Draper,

Lee Fairlie,

Louvina E. van der Laan,

Masebole Masenya,

H. Simon Schaaf,

Lubbe Wiesner,

Jennifer Norman,

Rob E. Aarnoutse,

Mats O. Karlsson,

Paolo Denti,

Anneke C. Hesseling

Publication year - 2021

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkab336

Subject(s) - medicine , pharmacokinetics , rifampicin , cohort , dosing , adverse effect , population , cohort study , pharmacology , tuberculosis , environmental health , pathology

Rifampicin doses of 40 mg/kg in adults are safe and well tolerated, may shorten anti-TB treatment and improve outcomes, but have not been evaluated in children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research